Targeting Cancer Metabolism

The understanding that oncogenes can have profound effects on cellular metabolism and the discovery of mutations and alterations in several metabolism-related enzymes—isocitrate dehydrogenase 1 (IDH1), isocitrate dehydrogenase 2 (IDH2), succinate dehydrogenase (SDH), fumarate hydratase (FH), and pyruvate kinase M2 (PKM2)—has renewed interest in cancer metabolism and renewed hope of taking therapeutic advantage of cancer metabolism. Otto Warburg observed that aerobic glycolysis was a characteristic of cancer cells. More than 50 years later, we understand that aerobic glycolysis and uptake of glutamine and glycine allow cancer cells to produce energy (ATP) and the nucleotides, amino acids, and lipids required for proliferation. Expression of the MYC oncogene drives the increase in cellular biomass facilitating proliferation. PKM2 expression in cancer cells stimulates aerobic glycolysis. Among intermediary metabolism enzymes, mutations in SDH occur in gastointestinal stromal tumors and result in a pseudohypoxic metabolic milieu. FH mutations lead to a characteristic renal cell carcinoma. Isocitrate dehydrogenase (IDH1/2) mutations have been found in leukemias, gliomas, prostate cancer, colon cancer, thyroid cancer, and sarcomas. These recently recognized oncogenic metabolic lesions may be selective targets for new anticancer therapeutics. Clin Cancer Res; 18(20); 5537–45. ©2012 AACR.

[1]  J. Veuthey,et al.  Identification and Functional Expression of the Mitochondrial Pyruvate Carrier , 2012, Science.

[2]  M. V. Heiden,et al.  Targeting cancer metabolism: a therapeutic window opens , 2011, Nature Reviews Drug Discovery.

[3]  Eyal Gottlieb,et al.  Mitochondrial tumour suppressors: a genetic and biochemical update , 2005, Nature Reviews Cancer.

[4]  Katarzyna A. Broniowska,et al.  Pyruvate fuels mitochondrial respiration and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition. , 2012, The Biochemical journal.

[5]  Jonathan A Disselhorst,et al.  Quantitative assessment of heterogeneity in tumor metabolism using FDG-PET. , 2012, International journal of radiation oncology, biology, physics.

[6]  Jason W. Locasale,et al.  Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses , 2011, Science.

[7]  G. Kroemer,et al.  Mitochondrion as a novel target of anticancer chemotherapy. , 2000, Journal of the National Cancer Institute.

[8]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[9]  Ian Tomlinson,et al.  Molecular and Cellular Pathobiology Expression Profiling in Progressive Stages of Fumarate- Hydratase Deficiency: the Contribution of Metabolic Changes to Tumorigenesis , 2022 .

[10]  Suzie Chen,et al.  Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development , 2010, Pharmaceuticals.

[11]  J. Ricci,et al.  Cancer metabolism: current perspectives and future directions , 2012, Cell Death and Disease.

[12]  Anthony Mancuso,et al.  Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.

[13]  H. Lee,et al.  Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies , 2011, Clinical Cancer Research.

[14]  C. Antonescu,et al.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations , 2010, Proceedings of the National Academy of Sciences.

[15]  R. Deberardinis,et al.  Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? , 2012, Cell.

[16]  G. Kalna,et al.  Metabolic Profiling of Hypoxic Cells Revealed a Catabolic Signature Required for Cell Survival , 2011, PloS one.

[17]  I. Martínez-Reyes,et al.  AMPK and GCN2-ATF4 signal the repression of mitochondria in colon cancer cells. , 2012, The Biochemical journal.

[18]  Dirk Troost,et al.  Addressing diffuse glioma as a systemic brain disease with single-cell analysis. , 2012, Archives of neurology.

[19]  R. Milo,et al.  Rethinking glycolysis: on the biochemical logic of metabolic pathways. , 2012, Nature chemical biology.

[20]  J. Huse,et al.  IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma , 2012, Clinical Cancer Research.

[21]  G. Riggins,et al.  Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2 , 2012, Current opinion in oncology.

[22]  G. Kroemer,et al.  Mitochondria in cancer , 2006, Oncogene.

[23]  V. Mootha,et al.  Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation , 2012, Science.

[24]  L. de Geus-Oei,et al.  Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4. , 2012, Lung cancer.

[25]  M. Sanson,et al.  IDH 1 Gene Mutations : A New Paradigm in Glioma Prognosis and Therapy ? , 2010 .

[26]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[27]  J. Bussink,et al.  Targeting Hypoxia, HIF-1, and Tumor Glucose Metabolism to Improve Radiotherapy Efficacy , 2012, Clinical Cancer Research.

[28]  A. Maitra,et al.  Conceptual Framework for Cutting the Pancreatic Cancer Fuel Supply , 2012, Clinical Cancer Research.

[29]  Funda Meric-Bernstam,et al.  Metformin: a therapeutic opportunity in breast cancer , 2010 .

[30]  M. Heuser,et al.  Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML–BFM and DCOG study groups , 2011, Leukemia.

[31]  David E. Muench,et al.  c-Myc and Cancer Metabolism , 2012, Clinical Cancer Research.

[32]  S. Eckhardt,et al.  Clinical Applications of Metabolomics in Oncology: A Review , 2009, Clinical Cancer Research.

[33]  E. Gottlieb,et al.  Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer , 2006, Oncogene.

[34]  Heidi Lyng,et al.  Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance. , 2012, International journal of radiation oncology, biology, physics.

[35]  H. Christofk,et al.  Pyruvate kinase M2 is a phosphotyrosine-binding protein , 2008, Nature.

[36]  W. Shih,et al.  A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in metastatic melanoma. , 2010 .

[37]  P. Ward,et al.  Signaling in control of cell growth and metabolism. , 2012, Cold Spring Harbor perspectives in biology.

[38]  A. Grigoriadis,et al.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.

[39]  R. Sciot,et al.  Somatic mosaic IDH1 or IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome , 2011, Nature Genetics.

[40]  Marta Cascante,et al.  Metabolic network adaptations in cancer as targets for novel therapies. , 2010, Biochemical Society transactions.

[41]  A. Viale,et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.

[42]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[43]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[44]  Guy Cosnard,et al.  IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri , 2012, Neuropathology : official journal of the Japanese Society of Neuropathology.

[45]  K. Kinzler,et al.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.

[46]  C. Speyer,et al.  Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer , 2012, Breast Cancer Research and Treatment.

[47]  W. Linehan,et al.  Pseudohypoxic Pathways in Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[48]  M. V. Vander Heiden,et al.  Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. , 2011, Annual review of cell and developmental biology.

[49]  Hui Yang,et al.  IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives , 2012, Clinical Cancer Research.

[50]  R. Jain,et al.  Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. , 2011, Cancer cell.

[51]  Vladimir Valera Romero,et al.  The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. , 2011, Cancer cell.

[52]  Arul M Chinnaiyan,et al.  Metabolism unhinged: IDH mutations in cancer , 2011, Nature Medicine.

[53]  W. Linehan,et al.  UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. , 2010, Cancer genetics and cytogenetics.

[54]  Thomas Bourgeron,et al.  Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency , 1995, Nature Genetics.

[55]  Chi V Dang,et al.  Links between metabolism and cancer. , 2012, Genes & development.

[56]  O. Chinot,et al.  IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients , 2011, Journal of Neuro-Oncology.

[57]  Nita Ahuja,et al.  Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. , 2012, Cancer cell.

[58]  A. Tan,et al.  A phase I trial of riluzole and sorafenib in patients with advanced solid tumors and melanoma. , 2012 .

[59]  Christian M. Metallo,et al.  Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia , 2011, Nature.

[60]  E. Ruppin,et al.  Predicting selective drug targets in cancer through metabolic networks , 2011, Molecular systems biology.

[61]  S. Pfister,et al.  Hedgehog-mediated regulation of PPARγ controls metabolic patterns in neural precursors and shh-driven medulloblastoma , 2012, Acta Neuropathologica.

[62]  G. Kroemer.  Mitochondria in cancer , 2006, Oncogene.

[63]  Gabriela Kalna,et al.  Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase , 2011, Nature.

[64]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[65]  Claire Redin,et al.  A Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila, and Humans , 2012, Science.

[66]  Gary Natriello.  FOCUS , 1985, Digital-Age Innovation in Higher Education.

[67]  Masaru Tomita,et al.  Systems Biology, Metabolomics, and Cancer Metabolism , 2012, Science.

[68]  C. Stratakis,et al.  SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma–paraganglioma syndromes , 2009, Journal of internal medicine.

[69]  W. Linehan,et al.  Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic Addiction and Hypoxia-Inducible Transcription Factor 1α Stabilization by Glucose-Dependent Generation of Reactive Oxygen Species , 2009, Molecular and Cellular Biology.

[70]  David T. W. Jones,et al.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.

[71]  Michael S. Goldberg,et al.  Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression , 2012, The Journal of experimental medicine.

[72]  W. Parker.  Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer , 2009 .

[73]  E. Ruppin,et al.  Predicting Drug Targets and Biomarkers of Cancer via Genome-Scale Metabolic Modeling , 2012, Clinical Cancer Research.

[74]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[75]  T. Copetti,et al.  Anticancer Targets in the Glycolytic Metabolism of Tumors: A Comprehensive Review , 2011, Front. Pharmacol..

[76]  J. Cuezva,et al.  The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response. , 2012, Molecular cell.

[77]  O. Warburg.  On the origin of cancer cells. , 1956, Science.

[78]  玉田 真由美.  Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells , 2012 .

[79]  Takashi Tsukamoto,et al.  Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. , 2012, Cell metabolism.

[80]  M. Suematsu,et al.  Pyruvate Kinase M2: Multiple Faces for Conferring Benefits on Cancer Cells , 2012, Clinical Cancer Research.

[81]  R. Deberardinis,et al.  Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer , 2010, Oncogene.

[82]  Targeting glucose metabolism for cancer therapy , 2012 .

[83]  W. Linehan,et al.  A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. , 2012, Cancer genetics.

[84]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[85]  T. Fan,et al.  Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM) , 2009, Molecular Cancer.

[86]  A. Futreal,et al.  Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2 , 2011, Nature Genetics.

[87]  P. Sutphin,et al.  Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality , 2011, Science Translational Medicine.

[88]  W. Marston Linehan,et al.  Reductive carboxylation supports growth in tumor cells with defective mitochondria , 2011, Nature.

[89]  J. Rabinowitz,et al.  Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation , 2012, Proceedings of the National Academy of Sciences.

[90]  I. Martínez-Reyes,et al.  The mitochondrial bioenergetic capacity of carcinomas , 2010, IUBMB life.

[91]  N. Brock.  Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture. , 1989, Cancer research.

[92]  E. Holme,et al.  IDH2 Mutations in Patients with d-2-Hydroxyglutaric Aciduria , 2010, Science.

[93]  P. Meltzer,et al.  Immunohistochemical Loss of Succinate Dehydrogenase Subunit A (SDHA) in Gastrointestinal Stromal Tumors (GISTs) Signals SDHA Germline Mutation , 2013, The American journal of surgical pathology.

[94]  P. Carmeliet,et al.  Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[95]  Hui Yang,et al.  Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. , 2012, Genes & development.

[96]  M. Sanson,et al.  IDH1 gene mutations: a new paradigm in glioma prognosis and therapy? , 2010, The oncologist.

[97]  Jing Wu,et al.  Alterations of metabolic genes and metabolites in cancer. , 2012, Seminars in cell & developmental biology.

[98]  L. Cantley,et al.  Decoding key nodes in the metabolism of cancer cells: sugar & spice and all things nice , 2012, F1000 biology reports.

[99]  Peder E. Z. Larson,et al.  13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. , 2011, Cell metabolism.